Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury (AKI) remains a complication commonly seen among patients in intensive care unit (ICU) settings. Clopidogrel, a P2Y12 receptor inhibitor, has revealed anti-inflammatory, antioxidant, immunomodulatory, and anti-apoptotic effects. However, evidence regarding its survival benefit in critically ill patients with AKI remains limited. This study aims to evaluate the association between clopidogrel use and mortality in critically ill patients with AKI.
Using MIMIC-IV database, we conducted a retrospective cohort study including 28457 AKI patients, of whom 3344 were clopidogrel users. The primary outcome was 30-day all-cause mortality. Multivariable Cox proportional hazards models were used to assess the risk of death. In order to verify the robustness of the results, we employed various techniques such as inverse probability weighting (IPTW), pairwise algorithms (PA), overlap weights (OW), and standardized mortality ratio weighting (SMRW).
After PSM (n = 6668), clopidogrel users showed a lower 30-day mortality (10.1% vs 12.0%, P = 0.012), with an adjusted HR of 0.83 (95%CI 0.72-0.96, P = 0.011). Kaplan-Meier analysis confirmed these findings, with clopidogrel users showing significantly higher survival probabilities at 30 days, 1 year, and 5 years (Log-rank P = 0.0017, 0.015, and 0.022, respectively). The protective effect lasted for 1 year (HR = 0.87, 95%CI 0.77-0.99) and 5 years mortality (HR = 0.89, 95%CI 0.79-1.00). After adjustment for potential confounders using PSM and propensity score, plus the use of IPTW, SMRW, PA, and OW, our results remained robust as the hazard ratios ranging from 0.42 to 0.58, all P values < 0.001.
Clopidogrel was associated with decreased mortality in critically ill AKI patients.
